Why is endosonography insufficient for residual diagnosis after neoadjuvant therapy for esophageal cancer? Solutions using muscle layer evaluation

Table 5 Patients’ characteristics in study 2

	pT0/1 (n = 10)	pT2/3 (n = 10)	P
Age (yr)
Median (range)	73 (52-79)	72 (43-81)	0.94
Sex
Male/Female	9/1	7/3	0.582
Tumor location
Ut, Mt, Lt/Ae	10/0	8/2	0.473
Clinical T stage
cT2, 3/cT4a, b	6/4	6/4	1
Preoperative treatment
NAC/CRT	6/4	6/4	1
Chemo regimen
CF/DCF	9/1	9/1	1
Total irradiation dose
38-40Gy/60Gy	2/2	4/0	0.429
Time of EUS after therapy (d)
Median (range)	37 (21-49)	29 (14-50)	0.172
Time of surgery after therapy (d)
Median (range)	41 (34-57)	37 (31-61)	0.471

Ut: Upper thoracic esophagus; Mt: Middle thoracic esophagus; Lt: Lower thoracic esophagus; Ae: Abdominal esophagus; CF: Cisplatin plus 5-fluorouracil; DCF: Docetaxel plus cisplatin plus 5-fluorouracil; NAC: Neoadjuvant chemotherapy; CRT: Chemoradiotherapy.